Morningstar

Repligen Corp RGEN

Morningstar Rating
Unlock
Stock XNAS Rating as of
$136.71 −2.33 (1.68%)
View Full Chart
As of Delayed Price Post-Trading: $142.97 +6.26

Company Report

View Archive

Repligen: Initiating Coverage With Narrow Moat Rating and $180 FVE; Shares Undervalued

Jay Lee

We are initiating coverage of Repligen with a narrow moat rating and fair value estimate of $180 per share. The firm is a leading provider of bioprocessing solutions for companies manufacturing biologic drugs, and its business lines include advanced filtration and fluid management systems, prepacked chromatography columns, proteins used in chromatography resins, and process analytic systems. We view the shares as modestly undervalued at current market prices.

Read Full Report

Price vs Fair Value

View History
RGEN is trading at a 267% premium.
Price
$139.04
Fair Value
$879.00
Uncertainty
High
1-Star Price
$489.00
5-Star Price
$338.00
Economic Moat
Btjtnl
Capital Allocation
Frlhzhtnyn

Bulls Say, Bears Say

Bulls

Repligen offers investors exposure to the rapidly growing and moatworthy bioprocessing industry and its market-leading product offerings.

Bears

Repligen’s adjusted EBITDA margins are around 20%, and it could take several years if not more to reach industry averages.

Show More

News

View All

Trading Information

Previous Close Price
$139.04
Day Range
$135.98–142.89
52-Week Range
$110.45–211.13
Bid/Ask
$136.51 / $143.15
Market Cap
$7.66 Bil
Volume/Avg
596,332 / 822,476

Key Statistics

Price/Earnings (Normalized)
118.84
Price/Sales
12.96
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
0.18%

Company Profile

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Small Growth
Total Number of Employees
1,783
Website
https://www.repligen.com

Competitors

Valuation

View More
Metric
RGEN
SRT3
DIM
Price/Earnings (Normalized)
 118.84181.1771.55
Price/Book Value
 3.916.084.50
Price/Sales
 12.962.446.16
Price/Cash Flow
 85.4514.5444.43
Price/Earnings
RGEN
SRT3
DIM

Financial Strength

Metric
RGEN
SRT3
DIM
Quick Ratio
 5.350.960.95
Current Ratio
 6.651.911.94
Interest Coverage
 1.902.042.54
Quick Ratio
RGEN
SRT3
DIM

Profitability

Metric
RGEN
SRT3
DIM
Return on Assets (Normalized)
 2.44%1.17%4.26%
Return on Equity (Normalized)
 3.36%4.78%10.55%
Return on Invested Capital (Normalized)
 2.92%3.71%8.01%
Return on Assets
RGEN
SRT3
DIM

Medical Instruments & Supplies Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
FzsbcxgkvFkh$170.4 Bil
 Becton Dickinson & Co
BDX
ScbjchxhNrsyvl$68.6 Bil
 Alcon Inc
ALC
MqkxnpyXwfgfc$48.7 Bil
 ResMed Inc
RMD
CcdzfjqsdlSwtnkgy$35.0 Bil
 Coloplast AS ADR
CLPBY
JftfynvfqTxjw$29.2 Bil
 West Pharmaceutical Services Inc
WST
BkxtrxzfsJlxq$21.6 Bil
 The Cooper Companies Inc
COO
BjbbjkkybLrmzmp$21.3 Bil
 Hologic Inc
HOLX
DqnylyhkTxzzf$18.4 Bil
 Baxter International Inc
BAX
JmdhfmsSgwks$17.9 Bil
 Align Technology Inc
ALGN
HlznnnrsyNkrnmlc$17.7 Bil

Sponsor Center